ClinicalTrials.gg

Essential Hypertension clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 481 studies for Essential Hypertension across more than 10 countries. 77 are recruiting or about to start. 414 of them are mainly about Essential Hypertension (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Isolated Systolic Hypertension too: 513 studies, 83 open.

Status

Completed
321
Status unknown
62
Recruiting
45
Not yet recruiting
28
Active, not recruiting
12
Terminated
8

Phase

Phase 3
126
Phase 4
64
Phase 1
55
Phase 2
51
Early Phase 1
3

Where

Korea, Republic of
99
China
76
United States
53
Germany
35
Japan
27
Italy
23

Who develops what

Add Essential Hypertension to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 31 programs from 15 companies, 31 with this as their studies’ main aim; 4 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Boryung Pharmaceutical, Celltrion and Shenzhen Salubris Pharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
ValsartanRecent, repeated
Evidence
  • NCT07700875 · Wuhan Createrna Science and Technology Co., Ltd · Phase 2 · comparator · “Sacubitril / valsartan 200 mg” · registered Jul 2026
  • NCT06771245 · CSPC Pharmaceutical Group Limited · Phase 3 · live · background · “Valsartan” · registered Jan 2025
  • NCT06716970 · Wuhan Createrna Science and Technology Co., Ltd · Phase 3 · live · comparator · “Sacubitril/valsartan 200mg” · registered Nov 2024
  • NCT06643819 · Chong Kun Dang Pharmaceutical · Phase 3 · live · comparator · “Valsartan” · registered Oct 2024
  • NCT02495324 · Boryung Pharmaceutical Co., Ltd · Phase 4 · comparator · “Valsartan” · registered Jul 2015
Novartis73% of its industry studiesUS: off-patent, 50 generics marketed34 studies
AmlodipineRecent, repeated
Evidence
  • NCT07704684 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 3 · comparator · “Active Comparator: Amlodipine Group” · registered Jul 2026
  • NCT06212648 · Shin Poong Pharmaceutical Co. Ltd. · Phase 2 · comparator · “SPC4001” · registered Nov 2022
  • NCT05288400 · servier · Phase 3 · comparator · “Norvasc 5mg tablet” · registered Feb 2022
  • NCT03156842 · Boryung Pharmaceutical Co., Ltd · Phase 3 · comparator · “Fimasartan/Amlodipine” · registered May 2017
  • NCT02738632 · ildong pharmaceutical · Phase 3 · comparator · “Telmisartan/Amlodipine” · registered Apr 2016
Novartis28% of its industry studiesUS: off-patent, 49 generics marketed33 studies
LosartanRecent, repeated
Evidence
  • NCT07704697 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 3 · comparator · “Active Comparator: Sacubitril/Allisartan Group” · registered Jul 2026
  • NCT05843162 · Chong Kun Dang Pharmaceutical · Phase 4 · live · comparator · “Losartan” · registered Mar 2023
  • NCT01541943 · Daewoong Pharmaceutical Co. LTD. · Phase 3 · comparator · “Losartan” · registered Feb 2012
  • NCT01307046 · Organon & Co. · Phase 3 · comparator · “Losartan” · registered Mar 2011
  • NCT01302691 · Merck & Co., Inc · Phase 3 · comparator · “Losartan potassium” · registered Feb 2011
Organon & Co.21% of its industry studiesUS: off-patent, 22 generics marketed22 studies
sacubitrilRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07704697 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 3 · comparator · “Active Comparator: Sacubitril/Allisartan Group” · registered Jul 2026
  • NCT07700875 · Wuhan Createrna Science and Technology Co., Ltd · Phase 2 · comparator · “Sacubitril / valsartan 200 mg” · registered Jul 2026
  • NCT06716970 · Wuhan Createrna Science and Technology Co., Ltd · Phase 3 · live · comparator · “Sacubitril/valsartan 200mg” · registered Nov 2024
Novartis62% of its industry studies23 studies

32 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
ValsartanApproved: US☆ Track1 live phase-3 study: NCT06863987lunan pharmaceutical group
EthanolApproved: US☆ Track1 live phase-3 study: NCT07083765Ablative Solutions, Inc.
QR12000☆ Track1 live phase-3 study: NCT06716970Wuhan Createrna Science and Technology Co., Ltd
AD-227B☆ Track1 live phase-3 study: NCT06441630Yuhan Corporation

The 4 in phase 3 with the nearest primary completion, of 31 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Jan 2027 est.SYH2062 · CSPC Pharmaceutical Group Limited · Phase 2 main aimNCT07940075 SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension . — primary endpoint: Changes in 24-hour ambulatory blood pressure (mSBP) from baseline at week 12 post-treatment · 360 enrolled
  • 1 Feb 2027 est.BR1400-1, BR1400-2, BR1400-3, BR1400-4, BR1400 · Boryung Pharmaceutical Co., Ltd · Phase 2 main aim+ BR1400-1, BR1400-B, BR1400-C vs BR1400-5NCT07373613 A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension — primary endpoint: Change from baseline to treatment of 8 weeks in MSSBP · 330 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Essential Hypertension studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Angiotensin receptor blockers (ARBs) 5 open · Calcium channel blockers 1 open · Diuretics 1 open · Thiazide diuretics 1 open · Mineralocorticoid receptor antagonists (MRAs) 1 open

Coming up

18studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger. 4 (9%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 11 (24%) take healthy volunteers.

Recruiting studies that take each age, of 45
AgeWomenMen
104 (9%)4 (9%)
1826 (58%)26 (58%)
3039 (87%)39 (87%)
4040 (89%)40 (89%)
5041 (91%)41 (91%)
6541 (91%)41 (91%)
7533 (73%)33 (73%)
8521 (47%)21 (47%)

Across all 481 studies, recruiting or not: 45% stop at 75 or younger and 23% at 65; 5% take children; 1% are for women only and 5% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Essential Hypertension studies take

Of 47 phase 3 interventional studies under Essential Hypertension, half reached primary completion within 17 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 12 mo1–8 · 18 studies——
Phase 217 mo9–40 · 16 studies——
Phase 317 mo11–24 · 47 studies16 mo11–24 · 45 studies—
Phase 424 mo18–36 · 22 studies——
Interventional, no phase20 mo8–48 · 80 studies—16 mo7–47 · 70 studies
Observational44 mo27–52 · 27 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 481. Browse all 481 → or search them.